Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Lucid Group Inc (LCID) Price & Performance

Boston Scientific CorporationTrade
Lucid Group IncTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Lucid Group Inc — how do they compare? Boston Scientific Corporation trades at $51.58 (market cap $74.19B), while Lucid Group Inc trades at $6.46 (market cap $2.64B). The key difference: Boston Scientific Corporation is far larger — about 28.1× Lucid Group Inc's market cap. Which is the better fit depends on your goals.

BSXLCID
Market Cap
$74.19B$2.64B
Sector
HealthConsumer Cyclical
52-Week High
$108.14$24.77
52-Week Low
$42.63$4.62
Enterprise Value
$86.27B$5.54B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Lucid Group Inc

Lucid Group (LCID) trades at $6.47, down 2.12% on the day, reflecting ongoing investor concerns over persistent losses and cash burn. The stock exhibits a bearish technical trend with key support at $6, while fundamentally, the company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by a -249.21% net income margin. Recent news highlights an operational reset aiming for $1.4 billion in cash savings and a delayed midsize EV launch to 2027.

The outlook remains challenging with significant execution risks, though a $10.50 analyst price target suggests potential upside if cost-cutting and new initiatives like robotaxi partnerships succeed. High cash burn and competitive pressures pose substantial risks to near-term stability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Lucid Group Inc

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Read more on LCID